S-100B concentrations predict disease-free survival in stage III melanoma patients (Q37425922)

20 August 2017

S-100B concentrations predict disease-free survival in stage III melanoma patients (English)

1 reference

20 August 2017

S Kruijff

1

1 reference

20 August 2017

E Bastiaannet

2

1 reference

20 August 2017

A C Muller Kobold

3

1 reference

20 August 2017

R J van Ginkel

4

1 reference

20 August 2017

A J H Suurmeijer

5

1 reference

20 August 2017

H J Hoekstra

6

1 reference

20 August 2017

1 December 2009

1 reference

Annals of Surgical Oncology

20 August 2017

1 reference

20 August 2017

16

1 reference

20 August 2017

12

1 reference

20 August 2017

3455-3462

1 reference

Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694.

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Diagnosis and treatment of cutaneous melanoma: state of the art 2006.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Sentinel-node biopsy or nodal observation in melanoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Follow-up in patients with localised primary cutaneous melanoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Radiation therapy following lymph node dissection in melanoma patients: treatment, outcome and complications

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Serological markers for melanoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Serum S100--a marker for disease monitoring in metastatic melanoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Elevated serum levels of S100 and survival in metastatic malignant melanoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

S100 protein serum levels in cutaneous malignant melanoma

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Evaluation of new putative tumor markers for melanoma

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Level of fluorodeoxyglucose uptake predicts risk for recurrence in melanoma patients presenting with lymph node metastases.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Serum markers for melanoma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Serum S100beta protein as a marker of disease activity in patients with malignant melanoma.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779363

Tumor markers in peripheral blood of patients with malignant melanoma: multimarker RT-PCR versus a luminoimmunometric assay for S-100

2 September 2018

1 reference

12 December 2020

S-100 protein in peripheral blood: a marker for melanoma metastases: a prospective 2-center study of 570 patients with melanoma

1 reference

12 December 2020

Evaluation of S-100beta assays for the prediction of recurrence and prognosis in patients with AJCC stage I-III melanoma

1 reference

12 December 2020

[Serum S100B protein and stage of cutaneous melanoma: a prospective study]

1 reference

12 December 2020

The value of serum S-100beta and interleukins as tumour markers in advanced melanoma

1 reference

12 December 2020

Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma

1 reference

12 December 2020

Comparison of Two Prognostic Markers for Malignant Melanoma: MIA and S100 β

1 reference

12 December 2020

Monitoring malignant melanoma with the S-100B tumour marker

1 reference

12 December 2020

Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma

1 reference

12 December 2020

On the release and half-life of S100B protein in the peripheral blood of melanoma patients

1 reference

12 December 2020

Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients

1 reference

12 December 2020

S100B protein detection in serum is a significant prognostic factor in metastatic melanoma

1 reference

12 December 2020

Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy

1 reference

12 December 2020

[S-100 beta protein in serum, a tumor marker in malignant melanoma-- current state of knowledge and clinical experience]

1 reference

12 December 2020

Prognostic value of serum S-100B in malignant melanoma

1 reference

12 December 2020

Prognostic value of serum analyses of S-100 protein beta in malignant melanoma

1 reference

12 December 2020

Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma

1 reference

12 December 2020

S-100 and NSE as serum markers in melanoma

1 reference

12 December 2020

Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma

1 reference

12 December 2020

Significance of serum S-100B in melanoma patients before and after sentinel node biopsy

1 reference

12 December 2020

[Trends in the incidence and death from cancer from 1989-2003 in The Netherlands]

1 reference

12 December 2020

Prognostic Implications of Protein S-100β Serum Levels in the Clinical Outcome of High-Risk Melanoma Patients

1 reference

12 December 2020

1 reference

12 December 2020

Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis

1 reference

12 December 2020

Clinical significance of serum S100 in metastatic malignant melanoma

1 reference

12 December 2020

Serum S-100 has prognostic significance in malignant melanoma

1 reference

12 December 2020

10.1245/S10434-009-0629-8

Identifiers

DOI

1 reference

Dimensions Publication ID

20 August 2017

0 references

1 reference

20 August 2017

PubMed publication ID

19636631

1 reference